AbbVie has completed a hat trick of phase 3 wins for its Parkinson’s disease prospect tavapadon, teeing the drugmaker up to file for FDA approval in 2025.
The Big Pharma acquired the once-daily oral dopamine D1/D5 receptor partial agonist in its $8.7 billion takeover of Cerevel Therapeutics.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,